• 1
    Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 0: 1016.
  • 2
    Jenkins SA, Baxter JN, Critchley M, et al. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. Br Med J 1997; 315: 133841.
  • 3
    Lin HC, Huang YT, Wu HL, et al. Effects of sustained-release lanreotide on hemodynamics in rats with portal vein stenosis. J Hepatol 1999; 31: 4828.
  • 4
    Escorsell A, Bordas JM, Castaneda B, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 10617.
  • 5
    Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32: 9304.
  • 6
    Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 64755.
  • 7
    Zoli M, Magalotti D, Ghigi G, Marchesini G, Pisi E. Transdermal nitroglycerin in cirrhosis. A 24-hour echo-Doppler study of splanchnic hemodynamics. J Hepatol 1996; 25: 498503.
  • 8
    Wahren J, Eriksson LS. The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol Suppl 1986; 119: 1038.
  • 9
    Mottet C, Sieber CC, Nauer A, et al. Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging echo-Doppler study. Hepatology 1998; 27: 9205.
  • 10
    McCormick PA, Seifalian AM, Stansby G, et al. Superior mesenteric artery blood flow in man measured with intra-arterial Doppler catheters: effect of octreotide. J Hepatol 1993; 17: 207.
  • 11
    Schiedermaier P, Goke B, Sauerbruch T. Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in patients with TIPS. Am J Gastroenterol 2001; 96: 221824.
    Direct Link:
  • 12
    Kuhn JM, Legrand A, Ruiz JM, Obach R, De Ronzan J, Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994; 38: 2139.
  • 13
    McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992; 16: 11806.
  • 14
    Albillos A, Rossi I, Iborra J, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994; 21: 8894.
  • 15
    Buonamico P, Sabba C, Garcia-Tsao G, et al. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: a double-blind randomized echo-Doppler study. Hepatology 1995; 21: 1349.
  • 16
    Vorobioff JD, Gamen M, Kravetz D, et al. Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial. Gastroenterology 2002; 122: 91622.
  • 17
    Jenkins SA, Nott DM, Baxter JN. Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. HPB Surg 1998; 11: 1321.
  • 18
    Zironi G, Rossi C, Siringo S, et al. Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study. Liver 1996; 16: 22534.
  • 19
    Schiedermaier P, Brensing KA, Göke B, et al. Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in healthy volunteers. Digestion 1999; 60: 13240.
  • 20
    Schiedermaier P, Harrison P, Arthur M, et al. Effect of the somatostatin analogue lanreotide on meal-stimulated portal blood flow in patients with liver cirrhosis. Digestion 2002; 65: 5660.
  • 21
    Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120: 1619.
  • 22
    Ludwig D, Schadel S, Bruning A, Schiefer B, Stange EF. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study. Dig Dis Sci 2000; 45: 101927.
  • 23
    Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A. Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 1997; 272: 1386976.
  • 24
    Beaumont V, Hepworth MB, Luty JS, Kelly E, Henderson G. Somatostatin receptor desensitization in NG108-15 cells. A consequence of receptor sequestration. J Biol Chem 1998; 273: 3317483.
  • 25
    De Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33: 84652.
  • 26
    Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123: 10139.
  • 27
    Sabba C, Ferraioli G, Buonamico P, et al. A randomized study of propranolol on postprandial portal hyperemia in cirrhotic patients. Gastroenterology 1992; 102: 100916.
  • 28
    Alvarez D, Miguez C, Podesta A, et al. Postprandial vascular response in patients with cirrhosis. Short-term effects of propranolol administration. Dig Dis Sci 1994; 39: 128893.
  • 29
    Albillos A, Perez-Paramo M, Cacho G, et al. Accuracy of portal and forearm blood flow measurements in the assessment of the portal pressure response to propranolol. J Hepatol 1997; 27: 496504.
  • 30
    Iwao T, Oho K, Sakai T, et al. Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. J Hepatol 1998; 28: 84755.
  • 31
    Schepke M, Raab P, Hoppe A, Schiedermaier P, Brensing KA, Sauerbruch T. Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis. Am J Gastroenterol 2000; 95: 29059.
    Direct Link:
  • 32
    Merkel C, Sacerdoti D, Bolognesi M, Bombonato G, Gatta A. Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. J Hepatol 1998; 28: 62230.
  • 33
    Siringo S, Bolondi L, Sofia S, et al. Circadian occurrence of variceal bleeding in patients with liver cirrhosis. J Gastroenterol Hepatol 1996; 11: 111520.
  • 34
    Mann NS, Hillis A, Mann SK, Buerk CA, Prasad VM. In cirrhotic patients variceal bleeding is more frequent in the evening and correlates with severity of liver disease. Hepatogastroenterology 1999; 46: 3914.
  • 35
    Merican I, Sprengers D, McCormick PA, Minoli G, McIntyre N, Burroughs AK. Diurnal pattern of variceal bleeding in cirrhotic patients. J Hepatol 1993; 19: 1522.
  • 36
    Garcia-Pagan JC, Feu F, et al. Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis. Hepatology 1994; 19: 595601.
  • 37
    Alvarez D, Golombek D, Lopez P, et al. Diurnal fluctuations of portal and systemic hemodynamic parameters in patients with cirrhosis. Hepatology 1994; 20: 1198203.
  • 38
    Alvarez D, De Las Heras M, Abecasis R, et al. Daily variation in portal blood flow and the effect of propranolol administration in a randomized study of patients with cirrhosis. Hepatology 1997; 25: 54850.